Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 4/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 3/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 3/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 2/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pi-103 SCHEMBL30387212 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29676244 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29352781 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29929906 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| Pi-103 SCHEMBL29527390 | 0.99 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10092301 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL30538318 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL13976099 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10092326 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 | |
| SCHEMBL10112597 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CGMTORPIK3C2BPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655449-B2 | Culture conditions to prolong/enhanced endodermal cell type for cell transplantation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-23 | — | — | US | claimed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| US-20210353605-A1 | METHODS FOR TREATING ORAL CANCERS | CHANG GUNG UNIVERSITY (TW) | 2021-11-18 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| US-20200377853-A1 | CULTURE CONDITIONS TO PROLONG/ENHANCED ENDODERMAL CELL TYPE FOR CELL TRANSPLANTATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-03 | — | — | US | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-10323228-B2 | Differentiation of hepatocyte-like cells from stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-18 | — | — | US | claimed |
| US-20170260503-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| US-20140315943-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-10-23 | — | — | US | claimed |
| WO-2012162372-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | claimed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | claimed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | claimed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-4729121-A2 | NOVEL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DERMAL DISORDERS | Drexel University (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3352755-B1 | TOPICAL COMPOSITION COMPRISING RAPAMYCIN FOR USE IN TREATING OR PREVENTING SEBORRHEIC KERATOSIS OR ACTINIC KERATOSIS | UNIV DREXEL (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12502414-B2 | Second generation Seneca Valley virus oncolytic therapy: compositions and methods thereof | SENECA THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240374764-A1 | COMBINATION RADIOTHERAPY | TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD. (AU) | 2024-11-14 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240307470-A1 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | SENECA THERAPEUTICS INC (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240293415-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4387667-A1 | COMBINATION RADIOTHERAPY | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240100107-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | SENECA THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4281549-A1 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | Seneca Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-4274593-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | Seneca Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | PALVELLA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | PALVELLA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| EP-3402468-B1 | INHIBITORS OF PI3K P-DELTA 110 FOR USE IN DELIVERY OF VIRUSES IN THE TREATMENT OF CANCER | UNIV LONDON QUEEN MARY (GB) | 2023-07-26 | — | — | EP | disclosed |
| EP-3402468-B1 | INHIBITORS OF PI3K P-DELTA 110 FOR USE IN DELIVERY OF VIRUSES IN THE TREATMENT OF CANCER | UNIV LONDON QUEEN MARY (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023137403-A2 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230201210-A1 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201210-A1 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11655449-B2 | Culture conditions to prolong/enhanced endodermal cell type for cell transplantation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | disclosed |
| WO-2023019308-A1 | COMBINATION RADIOTHERAPY | Telix International Pty Ltd (AU) | 2023-02-23 | — | — | WO | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20220387491-A1 | METHODS OF MAKING CELLULAR THERAPIES | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2022-12-08 | — | — | US | disclosed |
| EP-4054601-A1 | METHODS OF MAKING CELLULAR THERAPIES | Secura Bio, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-3474856-B1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20220249584-A1 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | SENECA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220241287-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| WO-2022159508-A1 | ARMED SENECA VALLEY VIRUS ONCOLYTIC THERAPY COMPOSITIONS AND METHODS THEREOF | SENECA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022150769-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | SENECA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2022-06-07 | — | — | US | disclosed |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3999087-A1 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | The Trustees of Columbia University in the City of New York (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220125794-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | disclosed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | disclosed |
| US-11241500-B2 | HSP90-targeting conjugates and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220031853-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220031673-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2022-02-03 | — | — | US | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-30 | — | — | US | disclosed |
| WO-2021252895-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-20210364495-A1 | CRISPR ASSOCIATED PROTEIN REACTIVE T CELL IMMUNITY | Charité-Universitätsmedizin Berlin (DE) | 2021-11-25 | — | — | US | disclosed |
| US-11179374-B2 | Compositions and methods for treating or preventing dermal disorders | DREXEL UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179374-B2 | Compositions and methods for treating or preventing dermal disorders | DREXEL UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210353605-A1 | METHODS FOR TREATING ORAL CANCERS | CHANG GUNG UNIVERSITY (TW) | 2021-11-18 | — | — | US | disclosed |
| US-20210338681-A1 | COMBINATION THERAPIES | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2021-11-04 | — | — | US | disclosed |
| US-11147818-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| WO-2021188849-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11110096-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11000513-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | PALVELLA THERAPEUTICS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021016194-A1 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | RACANIELLO VINCENT R (US) | 2021-01-28 | — | — | WO | disclosed |
| EP-3768833-A1 | CRISPR ASSOCIATED PROTEIN REACTIVE T CELL IMMUNITY | Charité - Universitätsmedizin Berlin (DE) | 2021-01-27 | — | — | EP | disclosed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2021-01-07 | — | — | US | disclosed |
| US-20200377853-A1 | CULTURE CONDITIONS TO PROLONG/ENHANCED ENDODERMAL CELL TYPE FOR CELL TRANSPLANTATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200360386-A1 | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions | UNITY BIOTECHNOLOGY, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200338083-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2020-10-29 | — | — | US | disclosed |
| EP-3380476-B1 | FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2020-09-30 | — | — | EP | disclosed |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-09-17 | — | — | US | disclosed |
| US-20200281903-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200281903-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | UNIV DREXEL (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3692988-A2 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND 5-FU, ANTI-VEGF ANTIBODY, CARBOPLATIN OR ABT-869 AND METHODS OF USE | Genentech, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10696688-B2 | Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-06-30 | — | — | US | disclosed |
| US-10695326-B2 | Compositions and methods for treating or preventing dermal disorders | DREXEL UNIVERSITY (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695326-B2 | Compositions and methods for treating or preventing dermal disorders | DREXEL UNIVERSITY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3007556-B1 | CELL STABILIZATION | BIOMATRICA INC (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | disclosed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-20200085960-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-03-19 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20200031845-A1 | FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-01-30 | — | — | US | disclosed |
| EP-2959014-B1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH INC (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019180243-A1 | CRISPR ASSOCIATED PROTEIN REACTIVE T CELL IMMUNITY | Charité-Universitätsmedizin Berlin (DE) | 2019-09-26 | — | — | WO | disclosed |
| EP-2791101-B1 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | VASCULAR BIOGENICS LTD (IL) | 2019-09-18 | — | — | EP | disclosed |
| US-20190216816-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2019118830-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-10323228-B2 | Differentiation of hepatocyte-like cells from stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-06-18 | — | — | US | disclosed |
| US-10300070-B2 | Metabolically-activated drug conjugates to overcome resistance in cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10300070-B2 | Metabolically-activated drug conjugates to overcome resistance in cancer therapy | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3216793-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | disclosed |
| EP-2928504-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2931316-B1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022156-A1 | Inhibitors Of PI3K P-Delta 110 For Use In Delivery Of Viruses In The Treatment Of Cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20190022156-A1 | Inhibitors Of PI3K P-Delta 110 For Use In Delivery Of Viruses In The Treatment Of Cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2019-01-24 | — | — | US | disclosed |
| US-20190015379-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-01-17 | — | — | US | disclosed |
| US-10155936-B2 | Parkin ligase activation methods and compositions | An2H Discovery Limited (IE) | 2018-12-18 | — | — | US | disclosed |
| US-20180280362-A1 | Novel Compositions and Methods for Treating or Preventing Dermal Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-04 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-20180243428-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2018153984-A1 | MTOR INHIBITOR-CORTICOID COMBINATION THERAPY FOR MULTIPLE SCLEROSIS | Universität Bern (CH) | 2018-08-30 | — | — | WO | disclosed |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180184644-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2018-07-05 | — | — | US | disclosed |
| WO-2018112176-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994913-B2 | Methods and compositions for detecting and treating drug resistant AKT mutant | GENENTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968619-B2 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968619-B2 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9956228-B2 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9956228-B2 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180055847-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9901583-B2 | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-02-27 | — | — | US | disclosed |
| US-9901583-B2 | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-02-27 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3269366-A2 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND LAPATINIB, AND METHODS OF USE | Genentech, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2972313-B1 | PORTED PARALLEL PLATE FLOW CHAMBER AND METHODS FOR USE THEREOF | RINKER KRISTINA D (CA) | 2018-01-03 | — | — | EP | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348314-A1 | COMBINATION THERAPIES | HCR COLLATERAL MANAGEMENT, LLC | 2017-12-07 | — | — | US | disclosed |
| US-9789193-B2 | Compositions for treating cancer and methods for making the same | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3228325-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170273988-A1 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-09-28 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-3217970-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | Del Mar Pharmaceuticals (CA) | 2017-09-20 | — | — | EP | disclosed |
| US-20170260503-A1 | DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-09-14 | — | — | US | disclosed |
| EP-3216793-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9757385-B2 | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757385-B2 | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| WO-2017122000-A1 | INHIBITORS OF PI3K P-DELTA 110 FOR USE IN DELIVERY OF VIRUSES IN THE TREATMENT OF CANCER | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2017-07-20 | — | — | WO | disclosed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | disclosed |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-08 | — | — | US | disclosed |
| WO-2017090058-A1 | FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-01 | — | — | WO | disclosed |
| US-20170151255-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-01 | — | — | US | disclosed |
| US-20170151255-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-06-01 | — | — | US | disclosed |
| US-20170136026-A1 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136026-A1 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-04-20 | — | — | US | disclosed |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-04-20 | — | — | US | disclosed |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-04-20 | — | — | US | disclosed |
| EP-2644204-B1 | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab | GENENTECH INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2644194-B1 | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel | GENENTECH INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20170095484-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-20170095484-A1 | METHOD OF TREATING RESISTANT NON-HODGKIN LYMPHOMA, MEDULLOBLASTOMA, AND/OR ALK+NON-SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| EP-2294072-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170065607-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-03-09 | — | — | US | disclosed |
| US-20170065607-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-03-09 | — | — | US | disclosed |
| EP-2717916-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170049784-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20170049784-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2017-02-23 | — | — | US | disclosed |
| EP-3122376-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | The Brigham and Women's Hospital, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9557320-B2 | Ported parallel plate flow chamber and methods for use thereof | SYANTRA INC. (CA) | 2017-01-31 | — | — | US | disclosed |
| WO-2016193955-A1 | COMBINATIONS OF KINASE INHIBITORS FOR TREATING COLORECTAL CANCER | STASSI GIORGIO (IT) | 2016-12-08 | — | — | WO | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20160312172-A1 | PORTED PARALLEL PLATE FLOW CHAMBER AND METHODS FOR USE THEREOF | SYANTRA INC. (CA) | 2016-10-27 | — | — | US | disclosed |
| US-20160279236-A1 | USE OF RAPAMYCIN AS VACCINE ADJUVANT AND PREPARATION METHOD THEREFOR | INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-29 | — | — | US | disclosed |
| US-20160279236-A1 | USE OF RAPAMYCIN AS VACCINE ADJUVANT AND PREPARATION METHOD THEREFOR | INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-29 | — | — | US | disclosed |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160160205-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | An2H Discovery Limited (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2016077264-A1 | DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME | DEL MAR PHARMACEUTICALS (CA) | 2016-05-19 | — | — | WO | disclosed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | disclosed |
| US-9334271-B2 | Purine derivatives and their use in the treatment of disease | NOVARITS AG (CH) | 2016-05-10 | — | — | US | disclosed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2419432-B9 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9254339-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160022757-A1 | THERAPEUTIC METHODS FOR TREATING SOLID TUMORS AND RELATED DIAGNOSTIC METHODS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2972313-A1 | PORTED PARALLEL PLATE FLOW CHAMBER AND METHODS FOR USE THEREOF | Rinker, Kristina, D. (CA) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| WO-2015189814-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2015-12-17 | — | — | WO | disclosed |
| US-20150329821-A1 | METHODS OF DIFFERENTIATING STEM CELLS INTO ONE OR MORE CELL LINEAGES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-11-19 | — | — | US | disclosed |
| WO-2015169951-A1 | METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2015-11-12 | — | — | WO | disclosed |
| US-20150320754-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2015-11-12 | — | — | US | disclosed |
| US-20150320755-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2015169953-A1 | METHOD OF TREATING GLIOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX GMBH (CH) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015168621-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-9174963-B2 | Triazine compounds as PI3 kinase and MTOR inhibitors | PFIZER INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| WO-2015160986-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015149001-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| EP-2254571-B1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH INC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150174263-A1 | COMPOSITIONS FOR TREATING CANCER AND METHODS FOR MAKING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-25 | — | — | US | disclosed |
| WO-2015078929-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-06-04 | — | — | WO | disclosed |
| US-20150119388-A1 | NOVEL PRO- AND CODRUG DERIVATIVES FOR NANOPARTICLE DELIVERY OF SELECT ANTICANCER AGENTS FORMED USING RAPIDLY CLEAVABLE PHENOLIC ESTER BRIDGES | THE CHILDREN'S HOSPITAL PHILADELPHIA (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119388-A1 | NOVEL PRO- AND CODRUG DERIVATIVES FOR NANOPARTICLE DELIVERY OF SELECT ANTICANCER AGENTS FORMED USING RAPIDLY CLEAVABLE PHENOLIC ESTER BRIDGES | THE CHILDREN'S HOSPITAL PHILADELPHIA (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119388-A1 | NOVEL PRO- AND CODRUG DERIVATIVES FOR NANOPARTICLE DELIVERY OF SELECT ANTICANCER AGENTS FORMED USING RAPIDLY CLEAVABLE PHENOLIC ESTER BRIDGES | THE CHILDREN'S HOSPITAL PHILADELPHIA (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2015018521-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | ONCOETHIX SA (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2015-01-08 | — | — | US | disclosed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140336166-A1 | NOVEL PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-20140315943-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8859542-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140274739-A1 | PORTED PARALLEL PLATE FLOW CHAMBER AND METHODS FOR USE THEREOF | UNIVERSITY OF CALGARY (CA) | 2014-09-18 | — | — | US | disclosed |
| WO-2014143696-A1 | PORTED PARALLEL PLATE FLOW CHAMBER AND METHODS FOR USE THEREOF | RINKER KRISTINA D (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2014130923-A2 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | GENENTECH, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140206678-A1 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT | KADMON CORPORATION, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206678-A1 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT | KADMON CORPORATION, LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8748421-B2 | Triazine compounds as P13 kinase and MTOR inhibitors | WYETH LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140140993-A1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140993-A1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140135370-A1 | TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2717916-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140066431-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066431-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066431-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-8663643-B2 | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8663643-B2 | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2014031856-A1 | COMBINATION THERAPY USING PI3 KINASE AND BRAF INHIBITORS | ONCONTHYREON INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| WO-2013188727-A2 | NOVEL PRO- AND CODRUG DERIVATIVES FOR NANOPARTICLE DELIVERY OF SELECT ANTICANCER AGENTS FORMED USING RAPIDLY CLEAVABLE PHENOLIC ESTER BRIDGES | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2013-12-19 | — | — | WO | disclosed |
| EP-2350053-B1 | Modulators of MTOR Complexes | WHITEHEAD BIOMEDICAL INST (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130323284-A1 | USE OF mTOR INHIBITORS TO TREAT BACTERIAL INFECTION | JAZZYA INVESTMENTS (ES) | 2013-12-05 | — | — | US | disclosed |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2419432-B1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20130296316-A1 | Antiparasitic Agents Based On mTOR Inhibitors | POLLASTRI MICHAEL P (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296316-A1 | Antiparasitic Agents Based On mTOR Inhibitors | POLLASTRI MICHAEL P (US) | 2013-11-07 | — | — | US | disclosed |
| US-8575159-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| EP-2644194-A2 | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel | Genentech, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2644204-A2 | Combinations of an anti-HER2 antibody-drug conjugate and pertuzumab | Genentech, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2640367-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2638907-A2 | Combinations of an anti-HER2 antibody-drug conjugate and lapatinib | Genentech, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461158-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8445486-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012171020-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012156379-A1 | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING | Universität Zürich (CH) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012155063-A1 | TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012118978-A1 | METHODS FOR TREATING ONCOVIRUS POSITIVE CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012103524-A2 | INHIBITORS OF MTOR KINASA AS ANTI- VIRAL AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-02 | — | — | WO | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2012087336-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088254-A1 | AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS | GENENTECH, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012068106-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012068106-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120107302-A1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120107302-A1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2012044641-A1 | 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| EP-2419432-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012019154-A2 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012006619-A2 | ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS | NORTHEASTERN UNIVERSITY (US) | 2012-01-12 | — | — | WO | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130654-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300483-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| EP-2294072-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2274010-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | Biogen Idec MA Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
| WO-2011005119-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | WO | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010120998-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010110686-A1 | PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| WO-2010074586-A1 | PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-07-01 | — | — | WO | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| WO-2010030967-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030727-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002954-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009155052-A1 | 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090298820-A1 | 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090291088-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291088-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291088-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143317-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009126304-A1 | THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009117277-A2 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2009097515-A2 | [A]-FUSED INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090192147-A1 | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2007030360-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7037915-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060058321-A1 | Fused heterolaryl derivatives | HAYAKAWA MASAHIKO | 2006-03-16 | — | — | US | disclosed |
| US-20050014771-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6838457-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| WO-2004017950-A2 | PHOSPHADIDYLINOSITOL 3,5-BIPHOSPHATE INHIBITORS AS ANTI-VIRAL AGENTS | PIRAMED LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695326-B2 | Compositions and methods for treating or preventing dermal disorders | MTOR, RPTOR, DEPTOR | PIK3CA 30/4885PIK3CG 142/4885MTOR 1/4885 |
| US-20230201210-A1 | COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | TIE1, KDR, ERBB2 | PIK3CA 809/4885PIK3CG 2220/4885MTOR 885/4885 |
| US-20160158246-A1 | METHOD OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A BET-BROMODOMAIN INHIBITOR | BRD4, BRD7, BCL6 | PIK3CA 3277/4885PIK3CG 4001/4885MTOR 3843/4885 |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | PIK3CA 4439/4885PIK3CG 3832/4885MTOR 2937/4885 |
| US-20190022156-A1 | Inhibitors Of PI3K P-Delta 110 For Use In Delivery Of Viruses In The Treatment Of Cancer | PI4KA, PIK3CA, PIK3R4 | PIK3CA 2/4885PIK3CG 7/4885MTOR 543/4885 |
| US-20150119388-A1 | NOVEL PRO- AND CODRUG DERIVATIVES FOR NANOPARTICLE DELIVERY OF SELECT ANTICANCER AGENTS FORMED USING RAPIDLY CLEAVABLE PHENOLIC ESTER BRIDGES | NR1H3, NR1H2, CYP46A1 | PIK3CA 1519/4885PIK3CG 2697/4885MTOR 1872/4885 |
| US-20150320755-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CA 24/4885PIK3CG 30/4885MTOR 191/4885 |
| US-11179374-B2 | Compositions and methods for treating or preventing dermal disorders | MTOR, RPTOR, DEPTOR | PIK3CA 30/4885PIK3CG 142/4885MTOR 1/4885 |
| US-20150320773-A1 | TREATMENT OF INFLAMMATION | CD14, TLR2, TLR4 | PIK3CA 2517/4885PIK3CG 1910/4885MTOR 1549/4885 |
| US-20160153049-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DRUG RESISTANT AKT MUTANT | PIK3CA, PIK3C2B, PIK3CG | PIK3CA 1/4885PIK3CG 3/4885MTOR 20/4885 |
| US-20210401987-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | MMP1, MMP8, CCL11 | PIK3CA 3484/4885PIK3CG 2628/4885MTOR 2177/4885 |
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | PIK3CA 2451/4885PIK3CG 2526/4885MTOR 4841/4885 |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | MTOR, PIK3CA, PIK3R3 | PIK3CA 2/4885PIK3CG 18/4885MTOR 1/4885 |
| US-20200085960-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PIK3CA 3406/4885PIK3CG 3503/4885MTOR 2636/4885 |
| US-20230263781-A1 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | MTOR, RICTOR, RPTOR | PIK3CA 14/4885PIK3CG 57/4885MTOR 1/4885 |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 21/4885MTOR 1/4885 |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 21/4885MTOR 1/4885 |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | PIK3CA 1/4885PIK3CG 4/4885MTOR 88/4885 |
| US-20170049784-A1 | METHOD OF TREATING ACUTE MYELOID LEUKEMIA AND/OR ACUTE LYMPHOBLASTIC LEUKEMIA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | MCL1, FLT3, HCLS1 | PIK3CA 4328/4885PIK3CG 4418/4885MTOR 4246/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | PIK3CA 2528/4885PIK3CG 2294/4885MTOR 4823/4885 |
| US-20170157141-A1 | METHOD OF TREATING LEUKEMIA USING PHARMACEUTICAL FORMULATION CONTAINING THIENOTRIAZOLODIAZEPINE COMPOUNDS | CCR10, HRH4, H1-10 | PIK3CA 3100/4885PIK3CG 4026/4885MTOR 4380/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | PIK3CA 1219/4885PIK3CG 1090/4885MTOR 255/4885 |
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885 |
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CA 24/4885PIK3CG 30/4885MTOR 191/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | PIK3CA 4439/4885PIK3CG 3832/4885MTOR 2937/4885 |
| US-20200338083-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CA 18/4885PIK3CG 45/4885MTOR 24/4885 |
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | PIK3CA 322/4885PIK3CG 455/4885MTOR 995/4885 |
| US-20120107302-A1 | COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | KDR, TIE1, ERBB2 | PIK3CA 1042/4885PIK3CG 2497/4885MTOR 1074/4885 |
| US-10155936-B2 | Parkin ligase activation methods and compositions | PINK1, XIAP, STUB1 | PIK3CA 2030/4885PIK3CG 1681/4885MTOR 3124/4885 |
| US-20180243428-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | PIK3CA 4107/4885PIK3CG 3541/4885MTOR 2281/4885 |
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | PIK3CA 2464/4885PIK3CG 3107/4885MTOR 4065/4885 |
| US-10300070-B2 | Metabolically-activated drug conjugates to overcome resistance in cancer therapy | GOT2, GOT1, PCK2 | PIK3CA 705/4885PIK3CG 1739/4885MTOR 858/4885 |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | BTK, BCL6, BCL6B | PIK3CA 322/4885PIK3CG 455/4885MTOR 995/4885 |
| US-11679101-B2 | Anhydrous compositions of mTOR inhibitors and methods of use | MTOR, RICTOR, RPTOR | PIK3CA 14/4885PIK3CG 57/4885MTOR 1/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885PIK3CG 3107/4885MTOR 2086/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885 |
| US-20170105998-A1 | METABOLICALLY-ACTIVATED DRUG CONJUGATES TO OVERCOME RESISTANCE IN CANCER THERAPY | GOT2, GOT1, PCK2 | PIK3CA 705/4885PIK3CG 1739/4885MTOR 858/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3CG 11/4885MTOR 27/4885 |
| US-20210000966-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90AA1, HSP90B1 | PIK3CA 3406/4885PIK3CG 3503/4885MTOR 2636/4885 |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 21/4885MTOR 1/4885 |
| US-20090298820-A1 | 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3C2B | PIK3CA 2/4885PIK3CG 8/4885MTOR 1/4885 |
| US-11351209-B2 | Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer | PI4KA, PIK3CA, PIK3R4 | PIK3CA 2/4885PIK3CG 7/4885MTOR 543/4885 |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | PIK3CA 4/4885PIK3CG 8/4885MTOR 1/4885 |
| US-20240016810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS | TARDBP, PIKFYVE, FUS | PIK3CA 252/4885PIK3CG 141/4885MTOR 806/4885 |
| US-20220241287-A1 | COMBINATION THERAPIES | FLT3, TLR3, BTK | PIK3CA 100/4885PIK3CG 216/4885MTOR 419/4885 |
| US-20140315943-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH MTOR/P13K INHIBITORS | MTOR, HSP90AB1, HSP90AA1 | PIK3CA 18/4885PIK3CG 143/4885MTOR 1/4885 |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885PIK3CG 21/4885MTOR 1/4885 |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | PIK3CA 2030/4885PIK3CG 1681/4885MTOR 3124/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | PIK3CA 36/4885PIK3CG 53/4885MTOR 1/4885 |
| US-20170151255-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER AND/OR SMALL CELL LUNG CANCER USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC19A2, TBXA2R | PIK3CA 3623/4885PIK3CG 4443/4885MTOR 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.